A China-based publicly listed enterprise specialized in blood purification is seeking to collaborate with early stage businesses with advanced technologies that are a strategic fit for its product pipeline. Equity investment size can be flexible but typically ranges from US$0.5-5 million. The firm can also consider collaborative research, licensing, and merger and acquisition. The firm is looking for new opportunities globally with a focus on the US.

The firm is interested in medical devices in the hematology, liver diseases, and cardiovascular diseases fields. The firm prefers post-prototype products with preclinical and clinical validation. Products should have a strategic angle with the firm’s pipeline of products.

The firm is looking for experienced management teams with sector expertise. The firm is interested in distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Canada-based venture capital firm makes investments with an average size of $5 million with reserves left for follow-on rounds. The firm seeks to make 4-5 new investments per year, and typically co-invests in seed, venture and series A investments at $50,000 – $1M per company. The firm has partnerships with medical software/device, fintech and ICT funds in which the firm will pass on deal flow. The firm has particular preference to companies located in North America, though is open to Australia and Western Europe depending on the opportunity. The firm does not request distribution rights for international investments.

The firm is interested in early-stage wearable technology and software-enabled technology, particularly ones that can improve hospital operations. The firm does not have a preference for any specific indication areas. The firm does not have revenue requirements for wearable technology and is not particularly interested in products that require regulatory pathways. The firm is interested in companies that are in the development or clinical-stage but will only invest in healthcare IT companies if it is already established with positive cash flow. Outside of software and wearable technology, the firm will look at medical devices to evaluate and connect to partnered funds.

The firm values sweat equity but the firm will not make any investments into a company unless the founding team has invested their own funds into the company’s success. The firm takes a board seat when making any new investments and looks for strong, experienced management teams. The first question the firm will ask any new opportunity is whether or not they have experience in marketing, sales, startups, or the industry they are entering. The firm can provide strategic management if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital company based in Texas makes equity investments into early stage companies generally in Angel and Seed rounds. For early stage opportunities, the firm typically invests up to $.5 million dollars but is able to invest more or less depending on the opportunity. Additionally the firm partners with a large number of investors in China who are interested in later stage opportunities where they can invest $15M-$20M. The firm is looking for companies located in the United States and generally makes 2-3 new investments per year.

The firm is looking for companies in sectors of Healthcare IT, Medical Devices, Telemedicine, Mobile Health and Bioinformatics. The firm looks for companies that have at least a prototype of their product and has made investment into several companies that have pre-market approval. The firm is agnostic in terms of subsector and indication and is very open to review any companies in their sectors of interest. More recently the firm has also gained interest into companies that are interested in accessing China market for business and investment opportunities.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment. The firm is also open to syndication with other investors in certain cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture arm of a medtech corporation makes equity investments in life science companies, typically in venture rounds. The firm invests at a wide range of product development phases, from preclinical development (up to 18 months away from the first in-human clinical trials) to products that have received regulatory approval, but typically does not invest in products that are on the market. The fund is open to considering investments globally.

The firm invests in areas that are strategically important to its parent corporation, primarily the medical device sector and the diagnostics sector. Within diagnostics, the fund is interested in molecular diagnostics, point of care diagnostics, and immunoassay and clinical chemistry systems. The firm’s areas of interest include cardiovascular diseases, diabetes and ophthalmology. The fund also invests in infant nutrition and nutraceuticals.

The firm invests only in privately-held companies, but has no other fixed requirements for companies & management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com